Clinical trials: Chimeric Antigen Receptor T-cell Therapy
Lymphoproliferative Disorder, Multiple Myeloma
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric…
- Trial name
- NCT06630104
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Electronic Health Record Review
- Where
- 7 sites in United States
- Volunteers
- 82 people
- Sponsor
- Mayo Clinic
Immunotherapy
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
This is an experimental study to evaluate the safety and effectiveness of PSMA-targeted CAR-T cells in the treatment of castration-resistant prostate cancer.
- Trial name
- NCT05354375
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what…
- Conditions
- Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT07297667
- Testing
- Fludarabine, Cyclophosphamide, GCAR1
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Canadian Cancer Trials Group
B-Cell Non-Hodgkin Lymphoma
A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1194C CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell NonHodgkin Lymphoma.
- Trial name
- NCT07068906
- Testing
- CAR-T cells chimenric antigen receptor T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B-cell Acute Lymphoblastic Leukemia
Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）
The purpose of this study is to evaluate the safety and efficacy of IFN-α combined with CAR-T cell therapy in relapsed and refractory acute lymphoblastic leukemia (R/R ALL).
- Trial name
- NCT04534634
- Testing
- IFN-α combined with CAR-T cell therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lymphomas
CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
Currently, a majority of lymphomas cannot be cured by standard chemo-radiotherapy. Cluster of differentiation antigen 30 (CD30) is expressed in many lymphoma subtypes, such as Hodgkin lymphoma (HL) and anaplastic large cell…
- Trial name
- NCT02274584
- Testing
- Anti-CD30 CAR T cells
- Where
- 2 sites in United States, China
- Volunteers
- 20 people
- Sponsor
- Peking University
Leukemia, Acute Lymphoblastic
CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
This is a single center, single arm, open-label phase 2 study to determine the efficacy of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains…
- Trial name
- NCT02935543
- Testing
- CART 19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Pennsylvania
Relapsed or Refractory Neuroblastoma
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
The purpose of this first in human study is to determine the safety and feasibility of 1RG-CART therapy in patients with relapsed or refractory neuroblastoma.
- Trial name
- NCT02761915
- Testing
- Leukapheresis, Cyclophosphamide, Fludarabine
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Cancer Research UK
Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukaemia
CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia
The goal of this observational study is to evaluate the efficacy of the treatment with approved CAR-T cells in Italy in pediatric and adult patients with acute B-cell lymphoblastic leukemia.
- Trial name
- NCT07623655
- Volunteers
- 107 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myeloma
CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma
Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually relapse despite advancement in treatment strategies.
- Trial name
- NCT04727008
- Testing
- CXCR4 modified anti-BCMA CAR T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sichuan University
Systemic Lupus Erythematosus
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE).
- Trial name
- NCT06340750
- Testing
- LMY-920
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Luminary Therapeutics
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory…
- Trial name
- NCT06173518
- Testing
- AUTO1
- Where
- 14 sites in United States, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- Autolus Limited
AML
Donor-derived CAR-T Cells in the Treatment of AML Patients
This is a clinical study to evaluate the safety and efficacy of donor-derived CAR-T cells in the treatment of patients with relapsed or refractory acute myeloid leukemia in China.
- Trial name
- NCT04766840
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Febrile Neutropenia
Remote Temperature Monitoring of Adult Subjects Undergoing Outpatient Stem Cell Transplant or CAR-T Cell Therapy
IDION is currently seeking FDA approval for this device- the IDION iTempShield. It is a skin-safe, FDA complaint and non-invasive device that can read and monitor skin temperature.
- Trial name
- NCT05576220
- Testing
- IDION iTempShield
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- IDION Inc.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
To evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL
- Trial name
- Phase I/II (NCT06880913)
- Testing
- Nanobody-Based CD19/CD22 Tandem Dual CAR-T
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma
Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
The goal of this clinical trial is to study how approaches for manufacturing chimeric antigen receptor (CAR)-modified T (CAR-T) cells affect their in vivo persistence and therapeutic efficacy against B lymphoma.
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma
- Trial name
- MeCAR (NCT02652910)
- Testing
- CD19.CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinqiao Hospital of Chongqing
Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
This study is an open-label, single-arm, prospective, multicenter, phase I/II clinical trial. It adopts the two-stage optimal design proposed by Bryant and Day to investigate the efficacy, safety, and in vivo pharmacokinetic…
- Trial name
- NCT07324889
- Testing
- CD19/BCMA CAR-T
- Volunteers
- 24 people
- Sponsor
- Yihao Wang
B-cell Acute Lymphocytic Leukemia
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
The purpose of this study is to infusion CD19 CAR-T cells to the patients with relapsed and refractory CD19+ B cell leukemia, to assess the safety and feasibility of this strategy.
- Trial name
- NCT03263208
- Testing
- Cyclophosphamide, Fludarabine, CD19 CAR-T
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Relapsed or Refractory Large B-cell Lymphoma
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed…
- Trial name
- CORAL (NCT06788964)
- Testing
- Loncastuximab Tesirine, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Utah
Non Hodgkin Lymphoma
Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients
n this study, approximately 30 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) were recruited for a single reinfusion of IM19-CD28 and IM19-41BB CAR-T cells.
- Trial name
- NCT03528421
- Testing
- IM19, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.